Evidence

David Thompson joins OPEN Health as Chief Executive Officer for Evidence & Access

Retrieved on: 
Monday, March 21, 2022
Health, Organization, Growth, Access, Research, Doctor of Philosophy, 2021 Essex County Council election, Fullerton Health Group, Goal, Policy, Evidence, RWE, Management

LONDON, March 21, 2022 /PRNewswire/ -- OPEN Health is pleased to announce the appointment of David Thompson, PhD, as Chief Executive Officer for Evidence & Access.

Key Points: 
  • LONDON, March 21, 2022 /PRNewswire/ -- OPEN Health is pleased to announce the appointment of David Thompson, PhD, as Chief Executive Officer for Evidence & Access.
  • David joins OPEN Health with a wealth of global experience in this area.
  • Commenting on his appointment, David said, "I am thrilled to be given the opportunity to lead OPEN Health's Evidence & Access practice.
  • We are delighted to welcome him to OPEN Health and to our executive team."

CymaBay Reports Fourth Quarter and Year Ended December 31, 2021 Financial Results and Provides Corporate Update

Retrieved on: 
Thursday, March 17, 2022
Therapy, Liver support system, Conditional sentence, Liver, CEO, Cirrhosis, MD, Association, Food and Drug Administration, Twitter, Goal, GLOBE, Fibrosis, Annual report, Quarter, Disease, Security (finance), Population, Ursodeoxycholic acid, Institute of Liver and Biliary Sciences, American Association, Efficacy, Conference, LinkedIn, Leona, PBC, Industry, Hepatitis, Director, U.S. Securities and Exchange Commission, GPR119, Hypoglycemia, Safety, Primary biliary cholangitis, NASDAQ, Investor, Investment, Growth, Clinical trial, Board, European Medicines Agency, Endocrinology, Hand, ALP, Gilead, AASLD, COVID, American Association of Clinical Endocrinologists, Alkaline phosphatase, Research, Portal, Priority, Digital, Itch, Evidence, Pharmaceutical industry, Medicine, Management, Animal, Thakeham, Patient

Sujal Shah, President and CEO of CymaBay, stated, 2021 was a year of growth for CymaBay and included accomplishments that position CymaBay for long-term success.

Key Points: 
  • Sujal Shah, President and CEO of CymaBay, stated, 2021 was a year of growth for CymaBay and included accomplishments that position CymaBay for long-term success.
  • Despite these challenges, we have seen steady progress since re-initiating our development program in PBC in 2021.
  • Fourth Quarter and Year Ended December 31, 2021 Financial Results
    Research and development expenses for the three months ended December 31, 2021 and 2020 were $18.4 million and $10.7 million, respectively.
  • General and administrative expenses for the three months ended December 31, 2021 and 2020 were $6.1 million and $5.2 million, respectively.

ARC Core® Rated Level 1 "Strong" in Evidence for ESSA Initiative by Johns Hopkins University

Retrieved on: 
Friday, March 11, 2022
Level 1, Heart, ARC, K5, University, K12, School, Every Student Succeeds Act, Education sciences, Research, Privacy Office of the U.S. Department of Homeland Security, Institute, BLUE, Science, Johns Hopkins University, Reading, ESSA, Evidence, Consortium, Center, IES, Policy, Student, Motivation, CPRE, Literacy, CEO, Curriculum, United States Department of Education, Tutoring, Education

BLUE BELL, Pa., March 11, 2022 /PRNewswire-PRWeb/ -- American Reading Company (ARC) announced today that its (award-winning) ARC Core curriculum earned the highest rating as a Level 1 program demonstrating "Strong Evidence" of efficacy under the Every Student Succeeds Act (ESSA).

Key Points: 
  • BLUE BELL, Pa., March 11, 2022 /PRNewswire-PRWeb/ -- American Reading Company (ARC) announced today that its (award-winning) ARC Core curriculum earned the highest rating as a Level 1 program demonstrating "Strong Evidence" of efficacy under the Every Student Succeeds Act (ESSA).
  • Evaluated by Evidence for ESSA at John Hopkins University's Center for Research and Reform in Education, the "Strong Evidence" designation meets the U.S. Department of Education's federal funding standards and makes ARC Core a solid choice for Title I, Elementary and Secondary School Emergency Relief (ESSER), state, and district-level funding.
  • "To have ARC Core recognized as having strong evidence of effectiveness by Evidence for ESSA is an honor," said Jane Hileman, CEO and founder of American Reading Company.
  • American Reading Company is a diverse, mission-driven organization that works to ensure every student is reading on or above grade level.

Evident joins Valtech, creating a B2B digital powerhouse in Europe

Retrieved on: 
Thursday, March 3, 2022
Digital, Microsoft, Industry, Hybris (company), Culture, Growth, Solution, Time, Acquisition, Marketing, Linde, Atlas Copco, Wavin, B2B, Evidence, Aalberts, Azure, Commerce, Technology, Intershop, ROI, Sales, Vanderlande, Mazars, Salesforce

AMSTERDAM, March 3, 2022 /PRNewswire/ -- Valtech, a global business transformation agency, today announced the acquisition of B2B digital consultancy, Evident.

Key Points: 
  • AMSTERDAM, March 3, 2022 /PRNewswire/ -- Valtech, a global business transformation agency, today announced the acquisition of B2B digital consultancy, Evident.
  • Digital now touches every part of a B2B business, and with an industry facing more complexity than at any other time, companies are rightly investing in their digital experience.
  • Already positioned as a leader in the commerce and B2B sectors, in welcoming Evident, Valtech is now set to become a true B2B digital powerhouse.
  • The Netherlands- and Portugal-based digital consultancy Evident brings over two decades of experience delivering transformative solutions for B2B clients including Atlas Copco, Vanderlande, Aalberts Industries, NCOI and Mazars.

Evident joins Valtech, creating a B2B digital powerhouse in Europe

Retrieved on: 
Thursday, March 3, 2022
Digital, Microsoft, Industry, Hybris (company), Culture, Growth, Solution, Time, Acquisition, Marketing, Linde, Atlas Copco, Wavin, B2B, Evidence, Aalberts, Azure, Commerce, Technology, Intershop, ROI, Sales, Vanderlande, Mazars, Salesforce

AMSTERDAM, March 3, 2022 /PRNewswire/ -- Valtech, a global business transformation agency, today announced the acquisition of B2B digital consultancy, Evident.

Key Points: 
  • AMSTERDAM, March 3, 2022 /PRNewswire/ -- Valtech, a global business transformation agency, today announced the acquisition of B2B digital consultancy, Evident.
  • Digital now touches every part of a B2B business, and with an industry facing more complexity than at any other time, companies are rightly investing in their digital experience.
  • Already positioned as a leader in the commerce and B2B sectors, in welcoming Evident, Valtech is now set to become a true B2B digital powerhouse.
  • The Netherlands- and Portugal-based digital consultancy Evident brings over two decades of experience delivering transformative solutions for B2B clients including Atlas Copco, Vanderlande, Aalberts Industries, NCOI and Mazars.

Homology Medicines Announces Presentations on HMI-203 Investigational Gene Therapy for Hunter Syndrome and Broad Applicability of AAVHSC Platform for Lysosomal Storage Disorders at the 18th Annual WORLDSymposium™ Meeting

Retrieved on: 
Thursday, February 10, 2022
Hearing loss, Motion, Glycogen storage disease, Gene, Private Securities Litigation Reform Act, Phenylketonuria, Clinical trial, Adult, Therapy, Cross, MPS II, Maintenance, COVID-19, Caregiver, Health, SEC, I2S, Cell, ERT, Evidence, MLD, Antibody, Central nervous system, CNS, Hunter syndrome, Biomarker, JumpStart, Enzyme replacement therapy, Nasdaq, KOL, Safety, Gene editing, Pain, Lists of people executed in the United States, National, Disease, Glycosaminoglycan, Microdeletion syndrome, LAMP1, Paroxysmal nocturnal hemoglobinuria, GLOBE, Patient, IDS, Mark (given name), MPS, Tropism, PKU, PNH, Failure, II, Pharmaceutical industry, Phosphorus, Dentistry, Vaccine, IND, Hunting

BEDFORD, Mass., Feb. 10, 2022 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. (Nasdaq: FIXX), a genetic medicines company, announced today multiple presentations on HMI-203 gene therapy candidate for the treatment of Hunter syndrome (MPS II), which is being evaluated in juMPStart, a Phase 1 open-label, dose-escalation clinical trial in adults with Hunter syndrome. In oral platform presentations, key eligibility criteria and planned endpoints for the juMPStart trial were discussed and data from the HMI-203 IND-enabling studies were presented. Homology also shared patient, caregiver and key opinion leader (KOL) feedback on the unmet medical need in Hunter syndrome, despite the availability of enzyme replacement therapy (ERT), and the potential for a one-time gene therapy for patients that could impact peripheral and central nervous system (CNS) manifestations. These presentations at the 18th Annual WORLDSymposium™ Meeting also included data on Homology’s AAVHSC platform and potential to treat additional lysosomal storage disorders, including metachromatic leukodystrophy (MLD), based on CNS transduction in non-human primates (NHPs).

Key Points: 
  • These presentations at the 18th Annual WORLDSymposium Meeting also included data on Homologys AAVHSC platform and potential to treat additional lysosomal storage disorders, including metachromatic leukodystrophy (MLD), based on CNS transduction in non-human primates (NHPs).
  • These presentations highlight how Homologys gene therapy approach to Hunter syndrome and other lysosomal storage diseases is developed to target both the peripheral as well as the CNS manifestations of these multi-organ disorders, stated Albert Seymour, Ph.D., Chief Scientific Officer of Homology Medicines.
  • Lastly, in the poster titled, AAVHSCs and CNS-Targeting Gene Therapy for Lysosomal Storage Disorders, the potential of utilizing AAVHSCs for lysosomal storage disorders was presented.
  • Homologys clinical programs include HMI-102, an investigational gene therapy for adults with phenylketonuria (PKU); HMI-103, a gene editing candidate for PKU; and HMI-203, an investigational gene therapy for Hunter syndrome.

Mallinckrodt's Steven Romano Elected National Pharmaceutical Council Board Chair

Retrieved on: 
Thursday, November 4, 2021
Safety, Science, Pharmacovigilance, NewYork-Presbyterian Hospital, Head, MD, Biology, Research, Eli Lilly, University, Real, MBA, Value, Patient, Strategic Advisory Group of Experts, Eli, Health policy, Policy, Public policy, NPC, Director, MS, Eli Lilly and Company, Committee, Research-on-Research Committee, Senior, Privacy, Doctor of Pharmacy, Company, Bristol Myers Squibb, Board, MPH, Environment, Multimedia, Washington University in St. Louis, Evidence, Health, Doctor of Philosophy, Education, MedImmune, Inc. v. Genentech, Inc., Board of directors, Management, Pharmaceutical industry

WASHINGTON, Nov. 4, 2021 /PRNewswire/ -- The National Pharmaceutical Council (NPC) today announced that Steven Romano, MD, Executive Vice President and Chief Scientific Officer, Mallinckrodt Pharmaceuticals, has been elected Chair of NPC's Board of Directors for 2021-2022.

Key Points: 
  • WASHINGTON, Nov. 4, 2021 /PRNewswire/ -- The National Pharmaceutical Council (NPC) today announced that Steven Romano, MD, Executive Vice President and Chief Scientific Officer, Mallinckrodt Pharmaceuticals, has been elected Chair of NPC's Board of Directors for 2021-2022.
  • Dr. Romano has served on NPC's Board as Vice Chair for the past year.
  • "I am honored to be elected chairman of NPC's Board of Directors," Dr. Romano said.
  • The National Pharmaceutical Council is a health policy research organization dedicated to the advancement of good evidence and science, and to fostering an environment in the United States that supports medical innovation.

Agilent Receives FDA Companion Diagnostic Approval for Ki-67 IHC MIB-1 pharmDx in High-Risk Early Breast Cancer

Retrieved on: 
Wednesday, October 13, 2021
Research, FDA, Genetics, Biotechnology, Other Health, Health, Other Science, Science, Oncology, Risk assessment, Breast cancer, LinkedIn, American Joint Committee on Cancer, Risk, Disease management, EBC, Evidence, Association, Abemaciclib, Ki-67, NYSE, FDA, Agilent Technologies, Disease, IHC, Diagnosis, Patient, News, AJCC, Company, Recurrence, Connolly, Twitter, Eli Lilly and Company, Medical device

This is the first IHC assay measuring Ki-67 expression to receive FDA approval in the context of treatment with Verzenio and was developed in collaboration with Eli Lilly and Company.

Key Points: 
  • This is the first IHC assay measuring Ki-67 expression to receive FDA approval in the context of treatment with Verzenio and was developed in collaboration with Eli Lilly and Company.
  • Conventional methods for evaluating the risk of recurrence in EBC are based on staging and are performed according to standard clinical and pathological features of the disease.
  • However, these standard features may not capture the full risk of recurrence for individuals with EBC.
  • The American Joint Committee on Cancer has identified the Ki-67 biomarker as Level of Evidence III in diagnosing EBC due to its association with cellular proliferation.

Kansas Hospital Live on Evident EHR and TruBridge RCM Services to Better Manage Patient Care and Improve Financial Performance

Retrieved on: 
Tuesday, October 5, 2021
Technology, Hospitals, Software, Practice Management, Other Health, Physical Therapy, Managed Care, Health, Data Management, CAH, Running, Evidence, Pharmacy, Risk, Solution, Annual report, HFMA, Collection, Security (finance), Private Securities Litigation Reform Act, NASDAQ, U.S. Securities and Exchange Commission, Workforce, Income, Revenue cycle management, Patient, Mental health, Physician, Health, Theft, Hospital, LLC, Telecommunication, EHR, COVID-19, Technology, Radiology, RCM, City, Medicine, Evident, TruBridge, EVIDENT, TRUBRIDGE

After seeing the positive impact of these workforce management solutions, Girard Medical Center realized it wanted to expand its technology investment with Evident.

Key Points: 
  • After seeing the positive impact of these workforce management solutions, Girard Medical Center realized it wanted to expand its technology investment with Evident.
  • Girard Medical Center wanted a modern, advanced fully integrated EHR system to provide its entire staff with the efficiencies needed to better manage patient care and back-office operations.
  • Our goal at Girard Medical Center is to provide our patient community with accessible, compassionate and high-quality care.
  • Having a solid financial performance is critical for us to effectively serve the healthcare needs of the communities in Southeast Kansas.

CopperSmith® Announces Exhibition at the Kitchen & Bath Industry Show

Retrieved on: 
Saturday, September 11, 2021

Additionally, the exhibit will feature two 48" workstation copper sinks, a 72" copper bathtub, custom stainless steel range hood and copper fire pit.

Key Points: 
  • Additionally, the exhibit will feature two 48" workstation copper sinks, a 72" copper bathtub, custom stainless steel range hood and copper fire pit.
  • The company seeks to connect with current trade partners and expand its trade partner network by forming new introductions throughout the week.
  • The booth design was a collaboration between Shannon Anderson of Evidence Design and Ben Goldstein, Vice President of Design at World CopperSmith.
  • Founded in 2009 and headquartered in Minneapolis, World CopperSmith's vision is to build the world's leading custom metalwork platform.